10-Q: TG Therapeutics Reports Q2 2024 Results: Revenue Growth and Strategic Financing

TG Therapeutics reports a profitable second quarter driven by strong Briumvi sales and secures a new $250 million credit facility.

Summary

• TG Therapeutics reported a net income of $6.9 million for the three months ended June 30, 2024, a significant turnaround from a net loss of $47.6 million in the same period last year.
• Product revenue, primarily from Briumvi sales, reached $72.6 million in Q2 2024, compared to $16 million in Q2 2023.
• For the six months ended June 30, 2024, the company reported a net loss of $3.8 million, an improvement from a net loss of $86.8 million in the same period of 2023.
• Total revenue for the first half of 2024 was $136.9 million, including $123.1 million from product sales and $13.9 million from license, milestone, royalty and other revenue.
• The company secured a new $250 million credit facility with HealthCare Royalty and Blue Owl Capital, which was used to repay existing debt and fund a share repurchase program.
• As of June 30, 2024, TG Therapeutics had $217.3 million in cash, cash equivalents, and investment securities.
• The company believes its existing cash, cash equivalents, and investment securities, combined with projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing.

Sentiment

Score: 8

Explanation: The document shows a positive shift in financial performance with a profitable quarter and strong revenue growth. The new credit facility and share repurchase program also indicate financial stability and confidence. However, the company still faces risks and challenges, which prevents a perfect score.

Positives

• The company achieved profitability in the second quarter of 2024, a significant improvement from previous losses.
• Briumvi sales are showing strong growth, indicating successful commercialization efforts.
• The new credit facility provides financial stability and flexibility for future operations.
• The company received a substantial milestone payment related to the European launch of Briumvi.
• The company has a strong cash position to support ongoing operations and future growth.

Negatives

• The company still reported a net loss of $3.8 million for the first six months of 2024, despite a profitable second quarter.
• Operating expenses, particularly selling, general and administrative costs, remain high due to commercialization efforts.
• The company is still reliant on third-party manufacturers for its product supply.

Risks

• The company's success is heavily dependent on the continued market acceptance of Briumvi.
• The company faces substantial competition in the pharmaceutical market.
• The company's reliance on third-party manufacturers for its product supply increases the risk of supply disruptions.
• The company is subject to extensive regulation, including pricing controls, which may impact profitability.
• The company may need to raise additional capital in the future to fund its operations.

Future Outlook

The company believes its existing cash, cash equivalents, and investment securities, combined with projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing.

Industry Context

The report reflects the ongoing trend of pharmaceutical companies focusing on commercializing their products and managing financial resources effectively. The company's focus on B-cell diseases and the commercialization of Briumvi aligns with the growing market for targeted therapies in neurology and immunology.

Comparison to Industry Standards

• The revenue growth of TG Therapeutics is notable compared to other companies in the early stages of commercializing a new drug, such as Biogen with Tysabri and Ocrevus, which also experienced a ramp-up in sales after launch.
• The company's focus on a twice-yearly infusion for Briumvi is a competitive advantage compared to other MS treatments that require more frequent administration, similar to the strategy of Roche with Ocrevus.
• The securing of a $250 million credit facility is a common strategy for biotech companies to manage debt and fund operations, similar to how companies like BioMarin and Vertex have used debt financing to support their growth.
• The company's cash position of $217.3 million is relatively strong compared to other biotech companies of similar size, providing a buffer for ongoing operations and future investments.

Related Party Transactions

• The company incurred expenses of approximately $0.9 million for the six months ended June 30, 2024, related to shared personnel with Fortress Biotech, Inc.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the company's improved financial performance.
• Employees will benefit from the company's continued growth and stability.
• Patients will benefit from the continued availability of Briumvi and the development of new therapies.
• Creditors will benefit from the company's improved financial position and ability to repay its debts.

Next Steps

• The company plans to continue commercialization efforts for Briumvi in the U.S. and EU.
• The company will initiate a Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab in patients with RMS.
• The company will evaluate azercabtagene zapreleucel (azer-cel) in multiple autoimmune indications.
• The company will continue to evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Key Dates

Keywords

TG Therapeutics, Briumvi, ublituximab, multiple sclerosis, pharmaceutical, biotechnology, revenue, profitability, credit facility, commercialization, clinical trials, regulatory approval